Topic

Elaine Quilici is a freelance writer for 

Articles

Biopharma leaders and experts gather to discuss the future of pharma collaboration and tackling critical public health needs—together.

Capitalizing on Collaboration: The Effort to Sustain Pandemic-Partnering Momentum

Julian Upton is a contributing editor for 

A panel of pharma digital leaders discusses pathways for technology and data scale-up—and the skills, mindset, and C-suite influence needed to drive true digital transformation.

The Road to Digital Transformation: Roles and Requirements for Organizational Success

In this roundtable discussion, Steve Gens, Remco Munnik and James Kelleher explore the potential and the practicalities of building future processes on a single, joined-up content platform.

Is More Fluid Data & Document Management the Answer to Life Sciences Process Transformation?

Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.

Diversity & Inclusion in Pharma: Industry Leaders Bring Conversation to Forefront 

Recent roundtable brought together by Pharm Exec and Parexel features insights from leaders in the pharma industry on the current state and future of RWE.

Real-World Evidence: State-of-the-Art, Current Challenges and Future Vision

Lisa Henderson is the former group editorial director of 

Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.

Going Public During Lockdown: IPO Insights from Five Biotechnology CFOs

A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.

Leadership and Industry Image

A recent roundtable moderated by Dr. Scott Gottlieb gathered biopharma CEOs to share thoughts and strategies on navigating their companies through the COVID-19 outbreak.

Leadership During Pandemic

Pharm Exec sits down with a pair of big pharma compliance leaders to discuss the strategic move to principles-based policies and the impact of other emerging forces influencing industry compliance practice.

Compliance Disruptors

Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.

Executive Roundtable